Immuron Ltd (IMRN) Form 6-K — Sep 21, 2026
Immuron Limited (NASDAQ: IMRN; ASX: IMC) furnished a 6-K containing CEO Steven Lydeamore's presentation at the Coffee Microcaps Conference on September 22, 2026 in Sydney. The presentation recaps FY26 results: global sales revenue of A$7.7m up 6%, a net loss of A$(3.8)m (a A$1.4m improvement), and cash of A$9.0m at 30 June 2026, which management says funds operations through FY27-FY28. Strategically, Immuron is seeking partners for both pipeline assets: IMM-529 (FDA IND approved, ready for Phase 2 in C. difficile infection, with a Lumanity peak U.S.
Key figures
- Revenue
- A$7.7m FY26
- Net Income
- $(3.8)m FY26
- Revenue Yoy
- 6%
- Cash Position
- A$9.0m @ 30 June 2026
- Shares Outstanding
- 322848081
- Runway
- 24-month runway; cash to fund operations through FY27-FY28
- Market cap
- A$14.85m
- C diff us burden
- 400,000 cases and 30,000 deaths annually
- Options on issue
- 11767491
- Us sales revenue
- A$1.8m, up 7% (up 13% in USD)
- Gross profit margin
- 64.5% (0.9% decline)
- Travelan trial size
- n=851 trial completed
- Australian sales revenue
- A$5.8m, up 10%
- Imm529 preclinical efficacy
- Prevention 80% (P=0.0052); relapse protection 67% (P<0.01); treatment 78.6% (P<0.0001)
- Imm529 peak us sales estimate
- US$400 million (Lumanity)
- Imm124e peak us sales estimate
- US$102 million (Lumanity)
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.